With the Extended LAST STRONG study, we expect that extending this study to 3- and 5-year follow-up will increase knowledge on natural history of SELENON-RM and LAMA2-MD disease progression, and contribute to selecting relevant and selective clinical and functional outcome measures. This evidence concerns the gene LAMA2 and Menkes disease.